VEGFA and Hypertension: In a large meta-analysis of 77 clinical trials of VEGF signaling pathway (VSP) inhibitors, severe hypertension occurred in 7.4% of patients, arterial thromboembolism in 1.8%, myocardial ischemia in 1.7% and myocardial failure in 2.3%.